Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-18 DOI:10.1080/21645515.2023.2285089

Gui-Ling Chen, Yuan-Zheng Qiu, Kai-Qi Wu, Ying Wu, Yuan-Hui Wang, Yu-Ying Zou, Cong-Gao Peng, Jie Zhao, Chang Su, Jun-Heng Ma, Shao-Nan Ni, Xing Wang, Ting-Han Jin, Qi Jiang, Tong Guo, Yan Xu, Chao-Chao Huang, Qing Zhang, Kai-Li Liu, Li Ji, Han-Yu Yang, Chun-Lei Li, Yu-Wen Su, Xiang Lu, Lan-Juan Li

引用次数: 0

Abstract

Vaccination plays a key role in preventing morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to evaluate the safety and immunogenicity of ...

查看原文本刊更多论文

在 18 岁或 18 岁以上的中国参与者中接种 SARS-CoV-2 mRNA 疫苗 (SYS6006) 的安全性和免疫原性：两项随机、观察者盲法、安慰剂对照和剂量递增的 1 期临床试验

接种疫苗在预防严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）导致的发病率和死亡率方面发挥着关键作用。我们的目的是评估SARS-CoV-2疫苗的安全性和免疫原性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

自引率

8.30%

发文量

审稿时长

1 months

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.